The Promises and Challenges of Erythropoietin for Treatment of Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Neuromolecular medicine

• Publication date

  2019-01-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12017-019-08524-yPMID 30656553PMCID PMC6407698
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.

  2019cited by this paper
• Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.

  2018cited by this paper
• Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode.

  2018cited by this paper
• 2018 Alzheimer's disease facts and figures

  2018cited by this paper
• Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

  2018cited by this paper
• Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.

  2018cited by this paper
• CEPO-Fc (An EPO Derivative) Protects Hippocampus Against Aβ-induced Memory Deterioration: A Behavioral and Molecular Study in a Rat Model of Aβ Toxicity.

  2018cited by this paper
• Epileptic activity in Alzheimer's disease: causes and clinical relevance.

  2017cited by this paper
• Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain

  2017cited by this paper
• Therapeutics of Neurotransmitters in Alzheimer’s Disease

  2017cited by this paper
• Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends

  2017cited by this paper
• Fibril structure of amyloid-β(1–42) by cryo–electron microscopy

  2017cited by this paper
• Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor

  2017cited by this paper
• Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

  2017cited by this paper
• UvA-DARE ( Digital Academic Repository ) Targeting Neuroinflammation to Treat Alzheimer ' s Disease

  2017cited by this paper
• Targeting Neuroinflammation to Treat Alzheimer’s Disease

  2017cited by this paper
• Pericytes: new EPO-producing cells in the brain.

  2016cited by this paper
• 2016 Alzheimer's disease facts and figures

  2016cited by this paper
• CSF, blood-brain barrier, and brain drug delivery

  2016cited by this paper
• An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer’s Disease

  2016cited by this paper
• Downstream modulation of extrinsic apoptotic pathway in streptozotocin-induced Alzheimer's dementia in rats: Erythropoietin versus curcumin.

  2016cited by this paper
• Complement and microglia mediate early synapse loss in Alzheimer mouse models

  2016cited by this paper
• Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease

  2016cited by this paper
• Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment.

  2015cited by this paper
• Neuroinflammation in Alzheimer's disease.

  2015cited by this paper
• Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease.

  2015cited by this paper
• Blood–brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody

  2015cited by this paper
• Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.

  2015cited by this paper
• Risk Factors of Caregiver Burden Among Patients with Alzheimer's Disease or Related Disorders: A Cross-Sectional Study

  2015cited by this paper
• Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease.

  2015cited by this paper
• Alzheimer's disease risk genes and mechanisms of disease pathogenesis.

  2015cited by this paper
• Erythropoietin attenuates Alzheimer-like memory impairments and pathological changes induced by amyloid β42 in mice.

  2015cited by this paper
• Upcoming Meetings Related to Alzheimer's Disease

  2015cited by this paper
• Amyloid-β Impairs Synaptic Inhibition via GABAA Receptor Endocytosis

  2015influential reference
• Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease.

  2014cited by this paper
• Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease

  2014cited by this paper
• Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

  2014cited by this paper
• Transcytosis of macromolecules at the blood-brain barrier.

  2014cited by this paper
• Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

  2014cited by this paper
• Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?

  2014cited by this paper
• Contribution of Alzheimer disease to mortality in the United States

  2014cited by this paper
• Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.

  2014cited by this paper
• Current approaches to enhance CNS delivery of drugs across the brain barriers

  2014cited by this paper
• Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

  2013cited by this paper
• A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

  2013cited by this paper
• Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers

  2013cited by this paper
• Can infections cause Alzheimer's disease?

  2013cited by this paper
• Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

  2013cited by this paper
• Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ25-35 non-transgenic mouse model of Alzheimer’s disease

  2013cited by this paper
• Regulation of erythropoiesis by hypoxia-inducible factors.

  2013cited by this paper
• Physiology and Pharmacology of Erythropoietin

  2013influential reference
• Protective action of erythropoietin on neuronal damage induced by activated microglia

  2013cited by this paper
• Epidemiology of dementias and Alzheimer's disease.

  2012cited by this paper
• Drug Transport across the Blood–Brain Barrier

  2012cited by this paper
• Ultrasound-induced blood-brain barrier opening.

  2012cited by this paper
• Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.

  2012cited by this paper
• Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL

  2012cited by this paper
• Intranasal delivery of biologics to the central nervous system.

  2012cited by this paper
• Mitochondrial Dysfunction—A Pharmacological Target in Alzheimer's Disease

  2012cited by this paper
• From Mitochondrial Dysfunction to Amyloid Beta Formation: Novel Insights into the Pathogenesis of Alzheimer’s Disease

  2012cited by this paper
• Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer's disease

  2012cited by this paper
• Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer’s Disease

  2012cited by this paper
• Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid‐beta burden in Alzheimer’s disease models

  2012cited by this paper
• Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

  2011cited by this paper
• Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance

  2011cited by this paper
• Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse.

  2011cited by this paper
• Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia.

  2011cited by this paper
• Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy

  2011cited by this paper
• An Overview of APP Processing Enzymes and Products

  2010cited by this paper
• Drug Targeting of Erythropoietin Across the Primate Blood-Brain Barrier with an IgG Molecular Trojan Horse

  2010cited by this paper
• Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research.

  2010cited by this paper
• Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.

  2010cited by this paper
• Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!

  2010cited by this paper
• The maternal and fetal impacts of obesity and gestational diabetes on pregnancy outcome.

  2010cited by this paper
• Update on the use of memantine in Alzheimer’s disease

  2009cited by this paper
• Neuroprotective and symptomatological action of memantine relevant for alzheimer’s disease — a unified glutamatergic hypothesis on the mechanism of action

  2009cited by this paper
• Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood–brain barrier delivery in the mouse

  2009cited by this paper
• The clinical course of advanced dementia.

  2009cited by this paper
• Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway.

  2009cited by this paper
• Translational Medicine Lessons from Flurizan's Failure in Alzheimer's Disease (AD) Trial: Implication for Future Drug Discovery and Development for AD

  2009cited by this paper
• The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

  2009cited by this paper
• Alzheimer's disease drug development and the problem of the blood‐brain barrier

  2009cited by this paper
• Update on the use of memantine in Alzheimer's disease.

  2009cited by this paper
• Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study.

  2009cited by this paper
• Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers.

  2008cited by this paper
• Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers

  2008cited by this paper
• Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms.

  2008cited by this paper
• Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume

  2007cited by this paper
• Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat

  2007cited by this paper
• Mitochondrial Oxidative Stress Causes Hyperphosphorylation of Tau

  2007cited by this paper
• Brain Erythropoietin Receptor Expression in Alzheimer Disease and Mild Cognitive Impairment

  2007cited by this paper
• Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation

  2007cited by this paper
• Iron trafficking inside the brain

  2007cited by this paper
• Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases.

  2006cited by this paper
• Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo

  2006cited by this paper
• Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry

  2006cited by this paper
• The significance of neuroinflammation in understanding Alzheimer’s disease

  2006cited by this paper
• Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein

  2006cited by this paper
• Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

  2006cited by this paper
• Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection

  2006cited by this paper

• Longitudinal pharmacokinetic and safety studies of an antibody-erythropoietin fusion protein for Alzheimer's disease

  2025cites this paper
• Longitudinal pharmacokinetic and safety studies for dose optimization of a brain- penetrating erythropoietin for Alzheimer’s disease

  2025cites this paper
• Potential Applications of Natural Components of Traditional Chinese Medicine Delivery via Nanoparticle Drug Delivery Systems in the Treatment of Alzheimer’s Disease

  2025cites this paper
• Intramuscular delivery of recombinant AAV expressing EpoR76E improves memory and is neuroprotective in 5xFAD transgenics

  2025cites this paper
• Erythropoietin for Seizures and Epilepsy: Neuroprotective Effects, Mechanisms, and Contradictory Risks.

  2025cites this paper
• NeuroEPO plus (NeuralCIM®) in Alzheimer's disease: Post-trial observational follow-up study

  2025cites this paper
• Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease.

  2025cites this paper
• An Overview of Neuroprotective Effects of Erythropoietin Against Neurological Disorders: Beyond Erythropoiesis

  2025cites this paper
• Cognitive Performance Correlated with Hemoglobin Level in Patients with Chronic Kidney Disease: A Data Analysis from the National Health and Nutrition Examination Survey 2011–2014

  2025cites this paper
• Mitochondria, Mitophagy, Mitoptosis, and Programmed Cell Death: Implications from Aging to Cancer.

  2024cites this paper
• Shengmaisan combined with Liuwei Dihuang Decoction alleviates chronic intermittent hypoxia-induced cognitive impairment by activating the EPO/EPOR/JAK2 signaling pathway.

  2024cites this paper
• Comparison of the components of fresh Panax notoginseng processed by different methods and their anti-anemia effects on cyclophosphamide-treated mice.

  2024cites this paper
• A Novel Neuroprotective Derived Peptide of Erythropoietin Improved Cognitive Function in Vascular Dementia Mice

  2024cites this paper
• Ferroptosis, Iron Metabolism, and Forkhead Transcription Factors (FoxOs).

  2023cites this paper
• The therapeutic effects of erythropoietin and carbamylated erythropoietin derivatives in neurological and other disorders

  2023cites this paper
• Intron retention is a mechanism of erythropoietin regulation in brain cell models.

  2023cites this paper
• NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial

  2023cites this paper
• Effect of Carbamylated Erythropoietin in a Chronic Model of TNBS-Induced Colitis

  2023cites this paper
• The Effects of a Blood–Brain Barrier Penetrating Erythropoietin in a Mouse Model of Tauopathy

  2023cites this paper
• MOLECULAR MECHANISM OF PROMOTION, PROGRESSION AND POSSIBLE THERAPIES OF ALZHEIMER'S DISEASE

  2022influential citation
• Microbial Transglutaminase-Mediated Formation of Erythropoietin-Polyester Conjugates.

  2022cites this paper
• Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease.

  2022cites this paper
• Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease

  2022cites this paper
• Recombinant human erythropoietin protects long-term cultured ageing primary nerve cells by upregulating the PI3K/Akt pathway

  2022cites this paper
• Recombinant human erythropoietin ameliorates cognitive dysfunction of APP/PS1 mice by attenuating neuron apoptosis via HSP90β

  2022cites this paper
• Therapeutic Effect of Erythropoietin on Alzheimer’s Disease by Activating the Serotonin Pathway

  2022cites this paper
• Erythropoietin inhibits ferroptosis and ameliorates neurological function after spinal cord injury

  2022cites this paper
• Erythropoietin signaling in peripheral macrophages is required for systemic β‐amyloid clearance

  2022cites this paper
• Intraperitoneal Carbamylated erythropoietin improves memory and hippocampal apoptosis in beta amyloid rat model of Alzheimer’s disease through stimulating autophagy and inhibiting necroptosis

  2021cites this paper
• Erythropoietin promotes hippocampal mitochondrial function and enhances cognition in mice

  2021cites this paper
• The Potential Role of Hypoxia-Inducible Factor-1 in the Progression and Therapy of Central Nervous System Diseases

  2021cites this paper
• Erythropoietin promotes hippocampal mitochondrial function and enhances cognition in mice

  2021cites this paper
• fvEarly monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.

  2021cites this paper
• Cognitive Impairment and Dementia: Gaining Insight through Circadian Clock Gene Pathways

  2021cites this paper
• Erythropoietin and derivatives: Potential beneficial effects on the brain

  2021cites this paper
• Erythropoietin Gene Therapy Delays Retinal Degeneration Resulting from Oxidative Stress in the Retinal Pigment Epithelium

  2021cites this paper
• Sirtuins in metabolic disease: innovative therapeutic strategies with SIRT1, AMPK, mTOR, and nicotinamide

  2021cites this paper
• Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks

  2021influential citation
• Neurodegeneration, memory loss, and dementia: the impact of biological clocks and circadian rhythm

  2021cites this paper
• Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer’s disease

  2021cites this paper
• [The human lectin supersystems possessing probiotic and protective actions.]

  2020cites this paper
• Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1

  2020cites this paper
• Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative disease.

  2020cites this paper
• Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease

  2020cites this paper
• New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.

  2020cites this paper
• Intranasal applications in Alzheimer's treatment

  2020cites this paper
• Nicotinamide: Oversight of Metabolic Dysfunction through SIRT1, mTOR, and Clock Genes.

  2020cites this paper
• Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways

  2019cites this paper
• Erythropoietin as a Neuroprotective Molecule: An Overview of Its Therapeutic Potential in Neurodegenerative Diseases

  2019cites this paper
• Preserving Brain Function During Development and Aging with Erythropoietin.

  2019cites this paper
• Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice

  2019cites this paper